Analyst Price Targets — GLUE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 14, 2026 11:48 am | — | Piper Sandler | $37.00 | $23.99 | TheFly | Monte Rosa Therapeutics price target raised to $37 from $27.50 at Piper Sandler |
| January 7, 2026 7:27 pm | — | Jefferies | $31.00 | $23.29 | TheFly | Monte Rosa Therapeutics price target raised to $31 from $22 at Jefferies |
| January 7, 2026 3:05 pm | — | Wedbush | $37.00 | $24.31 | TheFly | Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush |
| December 17, 2025 9:28 am | Kelly Shi | Jefferies | $22.00 | $18.66 | StreetInsider | Monte Rosa Therapeutics (GLUE) PT Raised to $22 at Jefferies |
| December 16, 2025 10:24 am | — | Wells Fargo | $22.00 | $16.45 | TheFly | Monte Rosa Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo |
Latest News for GLUE
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to earnings of $0.23 per share a year ago.
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly announced unblinded safety data from MRT-8102 SAD/MAD cohorts continue to support favorable safety/tolerability profile and wide therapeutic window Company plans to initiate multiple Phase 2 studies…
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment
Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GLUE.
U.S. House Trading
No House trades found for GLUE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.